Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 7, 2017, Pages 1085-1097

  Gong, Xiaomei ^a   Li, Xuefei ^a   Jiang, Tao ^a   Xie, Huikang ^a   Zhu, Zhengfei ^b   Zhou, Fei ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Myeloid derived suppressor cells; PI3K AKT pathway; Programmed death ligand 1; Radiation resistance; Tumor infiltrating regulatory T cells

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CD8 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN KINASE B; RNA; STAT3 PROTEIN; TRIPARTITE MOTIF CONTAINING 21; TRIPARTITE MOTIF PROTEIN; UNCLASSIFIED DRUG; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL MIGRATION; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR IMMUNITY; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 85019900256     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.04.014     Document Type: Article

References (50)

1. Goldstraw, P., Chansky, K., Crowley, J., et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11 (2016), 39–51.
2. Auperin, A., Le Pechoux, C., Rolland, E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
3. Harrington, K.J., Billingham, L.J., Brunner, T.B., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 105 (2011), 628–639.
4. Burnette, B.C., Liang, H., Lee, Y., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71 (2011), 2488–2496.
5. Lee, Y., Auh, S.L., Wang, Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114 (2009), 589–595.
6. Draghiciu, O., Walczak, M., Hoogeboom, B.N., et al. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 134 (2014), 859–872.
7. Apetoh, L., Ghiringhelli, F., Tesniere, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007), 1050–1059.
8. Gardai, S.J., McPhillips, K.A., Frasch, S.C., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123 (2005), 321–334.
9. Ghiringhelli, F., Apetoh, L., Tesniere, A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15 (2009), 1170–1178.
10. Ma, Y., Adjemian, S., Mattarollo, S.R., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38 (2013), 729–741.
11. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005), 263–274.
12. Barker, H.E., Paget, J.T., Khan, A.A., Harrington, K.J., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15 (2015), 409–425.
13. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
14. Chen, J., Jiang, C.C., Jin, L., Zhang, X.D., Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27 (2016), 409–416.
15. Chen, N., Fang, W., Zhan, J., et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 10 (2015), 910–923.
16. Hong, S., Chen, N., Fang, W., et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology, 5, 2016, e1094598.
17. Ota, K., Azuma, K., Kawahara, A., et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 21 (2015), 4014–4021.
18. Atefi, M., Avramis, E., Lassen, A., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20 (2014), 3446–3457.
19. Dovedi, S.J., Adlard, A.L., Lipowska-Bhalla, G., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74 (2014), 5458–5468.
20. Deng, L., Liang, H., Burnette, B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
21. Boussiotis, V.A., Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375 (2016), 1767–1778.
22. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
23. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
24. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
25. Rizvi, N.A., Hellmann, M.D., Brahmer, J.R., et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 2969–2979.
26. Li, J., Li, X., Ren, S., et al. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 5 (2014), 7902–7916.
27. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
28. Dong, J.C., Gao, H., Zuo, S.Y., et al. Neuropilin 1 expression correlates with the Radio-resistance of human non-small-cell lung cancer cells. J Cell Mol Med 19 (2015), 2286–2295.
29. Marzec, M., Zhang, Q., Goradia, A., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 105 (2008), 20852–20857.
30. Tadmor, T., Attias, D., Polliack, A., Myeloid-derived suppressor cells—their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 153 (2011), 557–567.
31. Kanamori, M., Nakatsukasa, H., Okada, M., Lu, Q., Yoshimura, A., Induced regulatory T cells: their development, stability, and applications. Trends Immunol 37 (2016), 803–811.
32. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
33. Hughes, P.E., Caenepeel, S., Wu, L.C., Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol 37 (2016), 462–476.
34. Manegold, C., Dingemans, A.C., Gray, J.E., et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 12 (2016), 194–207.
35. Atkins, M.B., Larkin, J., Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst, 108, 2016, djv414.
36. Kronenberg, M., Rudensky, A., Regulation of immunity by self-reactive T cells. Nature 435 (2005), 598–604.
37. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
38. Tang, Q., Henriksen, K.J., Boden, E.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171 (2003), 3348–3352.
39. Galgani, M., De Rosa, V., La Cava, A., Matarese, G., Role of metabolism in the immunobiology of regulatory T cells. J Immunol 197 (2016), 2567–2575.
40. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12 (2012), 253–268.
41. Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
42. Hiniker, S.M., Chen, D.S., Reddy, S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5 (2012), 404–407.
43. Golden, E.B., Demaria, S., Schiff, P.B., Chacoua, A., Formenti, S.C., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
44. Noman, M.Z., Desantis, G., Janji, B., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211 (2014), 781–790.
45. Koh, J., Jang, J.Y., Keam, B., et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3. Oncoimmunology, 5, 2016, e1108514.
46. Wang, A., Wang, H.Y., Liu, Y., et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 41 (2015), 450–456.
47. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
48. Tokito, T., Azuma, K., Kawahara, A., et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 55 (2016), 7–14.
49. Chen, M.F., Chen, P.T., Chen, W.C., Lu, M.S., Lin, P.Y., Lee, K.D., The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget 7 (2016), 7913–7924.
50. Wu, C.T., Chen, W.C., Chang, Y.H., Lin, W.Y., Chin, M.F., The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep, 6, 2016, 19740.